We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Sobi Signs Global Licensing Agreement for Novel Neonatology Treatment from Only for Children Pharmaceuticals
News

Sobi Signs Global Licensing Agreement for Novel Neonatology Treatment from Only for Children Pharmaceuticals

Sobi Signs Global Licensing Agreement for Novel Neonatology Treatment from Only for Children Pharmaceuticals
News

Sobi Signs Global Licensing Agreement for Novel Neonatology Treatment from Only for Children Pharmaceuticals

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Sobi Signs Global Licensing Agreement for Novel Neonatology Treatment from Only for Children Pharmaceuticals"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

O4CP will be responsible for obtaining market authorizations and for manufacturing of drug product. Sobi will be accountable for the commercialization of the product on a global basis. The agreement includes an upfront payment by Sobi in the amount of 300 000 Euro and potential future milestones of a value up to approximately 1.7 million Euro. O4CP will also receive royalties on future commercial sales.

"We are pleased to enter into this partnership with O4CP to further the development of an important potential therapy for neonates. Sobi is committed to innovations in the pediatric and neonatal areas where there remains a high degree of unmet need for medicines specifically developed for these patients. The partnership with O4CP around bumetanide is an important step for us and will provide a perfect complement to Kiobrina® in the future," says Geoffrey McDonough, CEO of Sobi.

"Sobi understands the value of bringing medicines to neglected populations. The company has a strong market organization and global ambitions, and is therefore a perfect partner for us. The agreement will secure that this important treatment for neonates will reach the market," says Vincent Grek, President of O4CP.

Advertisement